|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Is endoscopic ultrasound examination necessary in the management of esophageal cancer?显示文摘Despite substantial efforts at early diagnosis, accurate staging and advanced treatments, esophageal cancer(EC) continues to be an ominous disease worldwide. Risk factors for esophageal carcinomas include obesity, gastroesophageal reflux disease, hard-alcohol use and tobacco smoking. Five-year survival rates have improved from 5% to 20% since the 1970 s, the result of advances in diagnostic staging and treatment. As the most sensitive test for locoregional staging of EC, endoscopic ultrasound(EUS) influences the development of an optimal oncologic treatment plan for a significant minority of patients with early cancers, which appropriately balances the risks and benefits of surgery, chemotherapy and radiation. EUS is costly, and may not be available at all centers. Thus, the yield of EUS needs to be thoughtfully considered for each patient. Localized intramucosal cancers occasionally require endoscopic resection(ER) for histologic staging or treatment; EUS evaluation may detect suspicious lymph nodes prior to exposing the patient to the risks of ER. Although positron emission tomography(PET) has been increasingly utilized in staging EC, it may be unnecessary for clinical staging of early, localized EC and carries the risk of false-positive metastasis(over staging). In EC patients with evidence of advanced disease, EUS or PET may be used to define the radiotherapy field. Multimodality staging with EUS, crosssectional imaging and histopathologic analysis of ER, remains the standard-of-care in the evaluation of early esophageal cancers. Herein, published data regarding use of EUS for intramucosal, local, regional and metastatic esophageal cancers are reviewed. An algorithm to illustrate the current use of EUS at The University of Texas MD Anderson Cancer Center is presented. | Tomas DaVee Jaffer A Ajani Jeffrey H Lee | 2017 | World Journal of Gastroenterology2017，23，5： | 11 |
| 2 | Medical management of gastric cancer:A 2014 update显示文摘Gastric cancer represents a serious health problem on a global scale. It is the second leading cause of cancer-related death worldwide. Novel therapeutic targets are desperately needed because the meager improvement in the cure rate of about 10% realized by adjunctive treatments to surgery is unacceptable as > 50% patients with localized gastric cancer succumb to their disease. Either postoperative chemoradiotherapy(United States),pre-and post-operative chemotherapy(Europe),and adjuvant chemotherapy after a D2 resection(Asia) can all be regarded as standards of care in the localized gastric cancer management. In metastatic disease the addition of trastuzumab to chemotherapy is standard of care in Her2 positive disease. In the HER2 negative population,the treatments remain limited.In the first line setting,the standard of care is a combination of fluoropyrimidine and platinum containing chemotherapy,with or without epirubicin or docetaxel.The results of targeted therapy trials have by and large been disappointing,but none of these trials looked at an appropriately enriched population.Finally there is a meager overall survival benefit in treating patients with metastatic disease in the second line setting,with either irinotecan,docetaxel or ramucirumab however none of these drugs have been compared head to head in a well-powered randomized controlled trial. | Elena Elimova Hironori Shiozaki Roopma Wadhwa Kazuki Sudo Qiongrong Chen Jeannelyn S Estrella Mariela A Blum Brian Badgwell Prajnan Das Shumei Song Jaffer A Ajani | 2014 | World Journal of Gastroenterology2014，20，38： | 10 |
| 3 | Endoscopic management of esophageal cancer显示文摘Esophageal cancer(EC)generally consists of squamous cell carcinoma(which arise from squamous epithelium)and adenocarcinoma(which arise from columnar epithelium).Due to the increased recognition of risk factors associated with EC and the development of screening programs,there has been an increase in the diagnosis of early EC.Early EC is amenable to curative therapy by endoscopy,which can be performed by either endoscopic resection or endoscopic ablation.Endoscopic resection consists of either endoscopic mucosal resection(preferred in cases of adenocarcinoma)or endoscopic submucosal dissection(preferred in cases of squamous cell carcinoma).Endoscopic ablation can be performed by either radiofrequency ablation,cryotherapy,argon plasma coagulation or photodynamic therapy,amongst others.Endoscopy can also assist in the management of complications post-esophageal surgery,such as anastomotic leaks and perforations.Finally,there is a growing role for endoscopy to manage end-of-life palliative symptoms,especially dysphagia.The growing use of esophageal stents,debulking therapy and dilation can assist in improving a patient’s quality of life.In this review,we examine the multiple roles of endoscopy in the management of patients with EC. | Osman Ahmed Jaffer A Ajani Jeffrey H Lee | 2019 | World Journal of Gastrointestinal Oncology2019，11，10： | 6 |
| 4 | Incidence of kidney stones in kidney transplant recipients:A systematic review and meta-analysis显示文摘AIM To evaluate the incidence and characteristics of kidney stones in kidney transplant recipients. METHODS A literature search was performed using MEDLINE, EMBASE, and Cochrane Database of Systematic Reviews from the inception of the databases through March 2016. Studies assessing the incidence of kidney stones in kidney transplant recipients were included. We applied a randomeffects model to estimate the incidence of kidney stones.RESULTS Twenty one studies with 64416 kidney transplant patients were included in the analyses to assess the incidence of kidney stones after kidney transplantation. The estimated incidence of kidney stones was 1.0%(95%CI: 0.6%-1.4%). The mean duration to diagnosis of kidney stones after kidney transplantation was 28 ± 22 mo. The mean age of patients with kidney stones was 42 ± 7 years. Within reported studies, approximately 50% of kidney transplant recipients with kidney stones were males. 67% of kidney stones were calcium-based stones(30% mixed CaO x/CaP, 27%CaO x and 10%CaP), followed by struvite stones(20%) and uric acid stones(13%).CONCLUSION The estimated incidence of kidney stones in patients after kidney transplantation is 1.0%. Although calcium based stones are the most common kidney stones aftertransplantation, struvite stones(also known as 'infection stones') are not uncommon in kidney transplant recipients. These findings may impact the prevention and clinical management of kidney stones after kidney transplantation. | Wisit Cheungpasitporn Charat Thongprayoon Michael A Mao Wonngarm Kittanamongkolchai Insara J Jaffer Sathick Tsering Dhondup Stephen B Erickson | 2016 | World Journal of Transplantation2016，6，4： | 2 |
| 5 | Venous thromboembolism prevention and perioperative management of anticoagulants显示文摘 | Mateo R Dutta S Jaffer A K | 2016 | Hospital Medicine Clinics2016，5，2： | 1 |
| 6 | Practical tips for warfarin dosing and monitoring显示文摘 | Jaffer A Bragg L | 2003 | C leve Clin J Med2003，70，4： | 1 |
| 7 | P21-activated Kinase 5 (Pak5) localizes to mitochondria and inhibits apoptosis by phosphorylating BAD 显示文摘 | Cotteret S Jaffer Z M Beeser A | 2003 | Mol Cell Biol2003，23，16： | 1 |
| 8 | Potential phosphorus recovery by struvite formation显示文摘 | Jaffer Y Clark T A Pearee P | 2002 | Water Research2002，36，： | 1 |
| 9 | Evolving Chemotherapy for advanced gastric cancer显示文摘 | JAFFER A | 2005 | The Oncologist2005，10，3： | 1 |
| 10 | Relation of lack of knowledge about dietary sodium to hospital readmission in patients with failure显示文摘 | Kallipara U K Jaffer O Amin A | 2008 | Am Cardiol2008，102，9： | 1 |
| 11 | Two-dimensional intravascular near-infrared fluorescence molecular imaging of inflammation in atherosclerosis and stent-induced vascular injury显示文摘 | Jaffer FA Calfon MA Rosenthal A | | 0，，25： | 1 |
| 12 | Potential phosphorus recovery by struvite formation显示文摘 | Jaffer ~ Clark T A Pearce P | 2002 | Water Research2002，36，7： | 1 |
| 13 | Seeing within :molecular imaging of the cardiovascular显示文摘 | JAFFER F A WEISSLEDER R | 2004 | Circ Res2004，94，4： | 1 |
| 14 | Unrecognized sleep apnea in the surgical patient:implications for the perioperative setting显示文摘 | Kaw R Michota F Jaffer A | 2006 | Chest2006，129，1： | 1 |
| 15 | An investigation into the useof human papillomavirus type 16 virus-like particles as a delivery vectorsystem for foreign proteins:N-and C-terminal fusion of GFP to the L1and L2 capsid proteins显示文摘 | Windram O P Weber B Jaffer M A | 2008 | Arch Virol2008，153，3： | 1 |
| 16 | Two-dimensional intravascular near-in- frared fluorescence molecular imaging of inflammation in atherosclerosis and stent-induced vascular injury 显示文摘 | Jaffer FA Calfon MA Rosenthal A | 2011 | J Am Coil Cardiol2011，57，25： | 1 |
| 17 | Conditions for efficient spin injection from a ferromagnetic metal into a semicon- ductor显示文摘 | FERT A JAFFERS H | 2001 | Phys Rev B2001，，18： | 1 |
| 18 | Potential phosphorus recovery by struvite formation显示文摘 | Jaffer Y Clark T A Pearce P | 2002 | Water research2002，36，7： | 1 |
| 19 | Enzymatic estimation of the extent of irreversible myocardium injury early after reperfusion 显示文摘 | Devries S R Jaffer A S Geltman E M | 1989 | Am Heart J1989，117，1： | 1 |
| 20 | Can we prevent a second ‘Gulf War syndrone'? Population-based healthcare for chronic idiopathic pain and fatigue after war显示文摘 | Engel CC Jaffer A Adkins J | 2004 | Adv Psychosom Med2004，25，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员